The spotlight centers on the company’s long-acting injectable therapies, which have significantly advanced the way HIV is treated and prevented, both in the U.S. and around the world.
As of May 2025, ViiV’s flagship products, including Cabotegravir (brand name: Apretude), have received widespread acclaim for their ability to maintain viral suppression and prevent HIV transmission through a bimonthly injection. These developments mark a historic shift in the fight against HIV, moving away from the burdens of daily oral regimens toward more sustainable, stigma-reducing solutions.
A Scientific Breakthrough with Global Impact
Originally developed through ViiV’s focused R&D programs in collaboration with GlaxoSmithKline (GSK) and Shionogi, Cabotegravir was the first and only long-acting injectable PrEP (pre-exposure prophylaxis) treatment approved by the FDA. It has demonstrated superior efficacy over traditional oral therapies, particularly among populations at higher risk of infection and those with limited access to consistent healthcare.
“Long-acting PrEP isn’t just a scientific advancement—it’s a tool for equity,” stated Deborah Waterhouse, CEO of ViiV Healthcare, during the firm’s 2025 Innovation Briefing. “It helps bridge the treatment gap, especially in underserved communities where daily medication can be difficult to manage.”
Recognized for Economic and Social Contributions
Beyond its pharmaceutical innovation, ViiV has also been celebrated for its positive economic impact in Connecticut and the broader Northeastern region. The company’s expansion of R&D operations and biomanufacturing jobs has led to local job creation, particularly in the Greater Hartford and Research Triangle Park areas.
The Connecticut Business and Industry Association (CBIA) commended ViiV for its role in boosting the state’s biotech profile, citing their job creation, university partnerships, and community health programs.
Driving the Future of Preventive Healthcare
Experts from the World Health Organization and UNAIDS have also highlighted ViiV’s contribution to the global HIV prevention agenda, pointing to their partnership-based distribution model across Africa, Asia, and Latin America. Their tiered pricing strategy and licensing agreements with generic manufacturers have improved accessibility and affordability of advanced therapies in low- and middle-income countries.
Looking Ahead
As ViiV continues to expand its pipeline in immunology and virology, the company remains committed to making HIV “a disease of the past.” Their focus now includes pediatric formulations and combination therapies, all designed to make prevention simpler and more accessible worldwide.
Source:
Details derived from official statements during ViiV Healthcare’s 2025 Innovation Briefing.
